Literature DB >> 16847591

Measurement by ELISA of complement factor 4 (C4) in the rat brain: necessity for removal of cerebrovascular proteins.

David A Loeffler1, Dianne M Camp.   

Abstract

Assessment of complement 4 (C4) levels in experimental animals is used as a marker for activation of the classical complement pathway. The objective of this study was to develop a method for measuring C4 concentrations in the rat brain. An ELISA (sensitivity = 0.5 ng C4/ml) was used to measure C4 in regional brain homogenates from Fischer rats cardiac-perfused with phosphate buffered saline to remove cerebrovascular contents, and from sham-perfused rats. Ventral midbrain C4 levels were increased (p < 0.001) versus frontal cortex and striatum in sham-perfused rats, whereas after perfusion there were no differences between brain regions. Removal of cerebrovascular contents decreased C4 by 43% in striatum, 52% in frontal cortex, and 69% in ventral midbrain (all p < 0.01 versus sham-perfused means). These results indicate that C4 in the rat brain can be measured quantitatively by ELISA provided that cerebrovascular proteins are removed by perfusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847591     DOI: 10.1007/s11064-006-9105-z

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  14 in total

1.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease.

Authors:  Y Matsuoka; M Picciano; B Malester; J LaFrancois; C Zehr; J M Daeschner; J A Olschowka; M I Fonseca; M K O'Banion; A J Tenner; C A Lemere; K Duff
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 2.  Targeting complement in therapy.

Authors:  M Kirschfink
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

3.  Specific inhibition of the classical complement pathway by C1q-binding peptides.

Authors:  A Roos; A J Nauta; D Broers; M C Faber-Krol; L A Trouw; J W Drijfhout; M R Daha
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

Review 4.  Complement therapeutics; history and current progress.

Authors:  B Paul Morgan; Claire L Harris
Journal:  Mol Immunol       Date:  2003-09       Impact factor: 4.407

Review 5.  The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection.

Authors:  A L D'Ambrosio; D J Pinsky; E S Connolly
Journal:  Mol Med       Date:  2001-06       Impact factor: 6.354

6.  Measurement of acute phase proteins in the rat brain: contribution of vascular contents.

Authors:  D A Loeffler; M C Linder; M Zamany; E Harel; M A Paul; H Baumann; P A LeWitt
Journal:  Neurochem Res       Date:  1999-10       Impact factor: 3.996

7.  Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2.

Authors:  Lauren Spielman; David Winger; Lap Ho; Paul S Aisen; Esther Shohami; Giulio Maria Pasinetti
Journal:  Acta Neuropathol       Date:  2001-11-24       Impact factor: 17.088

8.  The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.

Authors:  I G Bos; G J van Mierlo; W K Bleeker; G M Rigter; H te Velthuis; G Dickneite; C E Hack
Journal:  Int Immunopharmacol       Date:  2001-08       Impact factor: 4.932

9.  Postischemic hyperthermia induces Alzheimer-like pathology in the rat brain.

Authors:  R Sinigaglia-Coimbra; E A Cavalheiro; C G Coimbra
Journal:  Acta Neuropathol       Date:  2002-02-06       Impact factor: 17.088

10.  Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy.

Authors:  T Yamada; I Moroo; Y Koguchi; M Asahina; K Hirayama
Journal:  Acta Neurol Scand       Date:  1994-01       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.